Targeted miRNA Approach to Pediatric Diffuse Midline Glioma

Abstract

Researchers at the University of California, Davis have developed a treatment method leveraging let-7 microRNA restoration to combat aggressive pediatric diffuse midline gliomas with H3K27M mutations.

Full Description

This technology involves a novel therapeutic strategy targeting pediatric diffuse midline gliomas harboring the H3 K27M mutation, a form of aggressive brain tumor with poor prognosis. Utilizing miRNA sequencing, it was found that the tumor suppressor let-7 family of microRNAs is significantly downregulated in these mutant glioma cells compared to wild-type. The method delivers synthetic let-7 miRNA molecules, stabilized oligonucleotides, or gene vectors encoding let-7 precursors directly to tumor cells to restore their expression, thereby repressing oncogene activity, inhibiting tumor growth, and improving patient outcomes. Delivery systems include lipid nanoparticles, viral vectors, and polymer-based carriers designed for targeted, controlled administration. The approach also explores modulation of LIN28, a protein that blocks let-7 maturation, as an adjunct therapeutic intervention.

Applications

• Therapeutic development for pediatric diffuse midline gliomas and other H3K27M mutant gliomas. 
• RNA-based therapies targeting oncogenic pathways in brain tumors. 
• Precision medicine approaches in pediatric neuro-oncology. 
• Development of delivery platforms for microRNA therapeutics in CNS cancers. 
• Potential expansion into treatments for other cancers with let-7 microRNA dysregulation.

Features/Benefits

• Restores tumor-suppressor let 7 microRNAs reduced by the H3K27M mutation. 
• Inhibits core oncogenic programs that control tumor-cell growth and differentiation. 
• Enables precise spatial and temporal control by leveraging versatile delivery modalities. 
• Amplifies therapeutic impact by combining multiple let 7 family members and/or complementary regulatory RNAs. 
• Provides a potential systemic treatment option beyond radiation. 
• Addresses the lack of effective systemic therapies for aggressive pediatric diffuse midline gliomas with H3K27M mutation. 
• Counteracts mutation-driven suppression of let 7 tumor-suppressor microRNAs that drives uncontrolled proliferation. 
• Targets underlying genetic and epigenetic disease drivers that current options do not directly treat.

Patent Status

Patent Pending